

# SECURITIES AND EXCHANGE COMMISSION

## FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2013-01-28** | Period of Report: **2013-01-25**  
SEC Accession No. [0001209191-13-004660](#)

([HTML Version](#) on [secdatabase.com](#))

### REPORTING OWNER

**BRISTOW MICHAEL R**

CIK: **1266125**

Type: **4** | Act: **34** | File No.: **000-22873** | Film No.: **13552471**

### ISSUER

**ARCA biopharma, Inc.**

CIK: **907654** | IRS No.: **363855489** | State of Incorporation: **DE** | Fiscal Year End: **1231**  
SIC: **2835** In vitro & in vivo diagnostic substances

Mailing Address  
*8001 ARISTA PLACE  
SUITE 200  
BROOMFIELD CO 80021*

Business Address  
*8001 ARISTA PLACE  
SUITE 200  
BROOMFIELD CO 80021  
720-940-2200*

# FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Expires:	02/28/2011
Estimated average burden hours per response	0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <b>BRISTOW MICHAEL R</b>  (Last) (First) (Middle)  8001 ARISTA PLACE, SUITE 430  (Street)  BROOMFIELD, CO 80021  (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <b>ARCA biopharma, Inc. [ABIO]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)  <b>President and CEO</b>		
			3. Date of Earliest Transaction (Month/Day/Year) <b>01/25/2013</b>					
			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/25/2013		P		1,069,290	A	\$0.4676	1,069,290	I	By NFS Custodian for Michael Bristow's IRA
Common Stock								834,495	I	By Investocor Trust as sole trustee
Common Stock								280,071	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Common stock warrants (right to buy)	\$0.3801	01/25/2013		P		748,503		01/25/2013 <sup>(L)</sup>	01/25/2020	Common Stock	748,503	\$ 0	748,503	I	By NFS Custodian for Michael Bristow's IRA

Explanation of Responses:

1. The warrants are fully vested and exercisable upon issuance and have a contractual term of 7 years.

**Signatures**

/s/ Michael R. Bristow

\*\* Signature of Reporting Person

01/28/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**